Journal Article
. 2016 Mar; 24(1):161-170.
doi: 10.1007/s12282-016-0691-6.

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study

Junichi Kurebayashi 1 Tatsuya Toyama 2 Shuuji Sumino 3 Eri Miyajima 3 Tsukasa Fujimoto 3 
Affiliations
  • PMID: 27017207
  •     23 References
  •     6 citations

Abstract

Background: Leuprorelin acetate, a luteinizing hormone-releasing hormone agonist, is used worldwide in premenopausal women with hormone receptor-positive breast cancer. This study was conducted to assess the non-inferiority of the 6-month depot formulation, TAP-144-SR (6M) 22.5 mg to the 3-month depot formulation, TAP-144-SR (3M) 11.25 mg in postoperative, premenopausal patients with hormone receptor-positive breast cancer.

Methods: This was a 96-week phase III, randomized, open-label, parallel-group comparative study. All patients concomitantly received oral tamoxifen (20 mg daily). The primary endpoint was the suppression rate of serum estradiol (E2) to the menopausal level (≤30 pg/mL) from Week 4 through Week 48.

Results: In total, 167 patients were randomized to receive TAP-144-SR (6M) (n = 83) or TAP-144-SR (3M) (n = 84) and the E2 suppression rate was 97.6 and 96.4 %, respectively. The estimated between-group difference was 1.2 % (95 % confidence interval -5.2 to 7.8). The non-inferiority of TAP-144-SR (6M) to TAP-144-SR (3M) for E2 suppression was confirmed. As for safety, common adverse events were hot flush and injection site reactions including induration, pain, and erythema in both treatment groups, which were of ≤Grade 2 in severity and not serious. No significant between-group differences in safety profiles and tolerability were observed.

Conclusions: TAP-144-SR (6M) was not inferior to TAP-144-SR (3M) for its suppressive effect on serum E2. TAP-144-SR (6M) was also as well tolerated as TAP-144-SR (3M).

Keywords: Adjuvant endocrine therapy; Leuprorelin acetate 6-month depot; Luteinizing hormone–releasing hormone agonist; Ovarian function suppression; Premenopausal hormone receptor-positive breast cancer.

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
W Jonat, M Kaufmann, +14 authors, Zoladex Early Breast Cancer Research Association Study.
J Clin Oncol, 2002 Dec 19; 20(24). PMID: 12488406
The effect of therapeutic and supratherapeutic oral doses of nomegestrol acetate (NOMAC)/17β-estradiol (E2) on QTcF intervals in healthy women: results from a randomized, double-blind, placebo- and positive-controlled trial.
Pieter-Jan de Kam, Jacqueline van Kuijk, +2 authors, Torben Thomsen.
Clin Drug Investig, 2014 Apr 30; 34(6). PMID: 24777591
[A phase II pharmacological study of leuprolide acetate 6-month depot, TAP-144-SR (6M), in treatment-Nazve patients with prostatic cancer who received a single subcutaneous or intramuscular injection].
Emiko Komura, Tsukasa Fujimoto, +2 authors, Hideyuki Akaza.
Gan To Kagaku Ryoho, 2014 Jun 12; 41(5). PMID: 24917003
Hormonal therapies in young breast cancer patients: when, what and for how long?
Alexandre Christinat, Simona Di Lascio, Olivia Pagani.
J Thorac Dis, 2013 Jul 03; 5 Suppl 1. PMID: 23819026    Free PMC article.
Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Peter Schmid, Michael Untch, +8 authors, Kurt Possinger.
J Clin Oncol, 2007 Jun 20; 25(18). PMID: 17577027
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
J G Klijn, R W Blamey, +4 authors, Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer.
J Clin Oncol, 2001 Feb 24; 19(2). PMID: 11208825
Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.
Norikazu Masuda, Hiraji Iwata, +6 authors, Shinzaburo Noguchi.
Breast Cancer Res Treat, 2011 Jan 12; 126(2). PMID: 21221770
[Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Kenkichi Koiso, Hideyuki Akaza, +9 authors, Kiyoshi Yokokawa.
Hinyokika Kiyo, 2003 Mar 05; 48(12). PMID: 12613016
[Clinical phase III study on TAP-144-SR, an LH-RH agonist depot formulation, in patients with prostatic cancer].
Y Aso, S Kameyama, +7 authors, M Hosaka.
Hinyokika Kiyo, 1991 Mar 01; 37(3). PMID: 1906239
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Michael Gnant, Brigitte Mlineritsch, +18 authors, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Lancet Oncol, 2008 Aug 23; 9(9). PMID: 18718815
Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients.
Mehmet Koc, Pinar Polat, Selami Suma.
Radiother Oncol, 2002 Sep 21; 64(2). PMID: 12242127
The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery.
Takayoshi Kiba, Takashi Inamoto, +6 authors, Masanori Fukushima.
BMC Cancer, 2008 Nov 08; 8. PMID: 18990247    Free PMC article.
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients.
F Boccardo, A Rubagotti, +10 authors, P Marroni.
Cancer Chemother Pharmacol, 1999 May 13; 43(6). PMID: 10321505
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.
A Goldhirsch, J H Glick, +2 authors, H J Senn.
J Clin Oncol, 2001 Sep 18; 19(18). PMID: 11559719
Review.
Interval estimation for the difference between independent proportions: comparison of eleven methods.
R G Newcombe.
Stat Med, 1998 May 22; 17(8). PMID: 9595617
Highly Cited.
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Eiichi Shiba, Hiroko Yamashita, +5 authors, Tsukasa Fujimoto.
Breast Cancer, 2015 Feb 07; 23(3). PMID: 25655898    Free PMC article.
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
Meredith M Regan, Olivia Pagani, +12 authors, GroupSOFT and TEXT Investigators.
Breast, 2013 Oct 08; 22(6). PMID: 24095609    Free PMC article.
Adjuvant ovarian suppression in premenopausal breast cancer.
Prudence A Francis, Meredith M Regan, +28 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Dec 17; 372(5). PMID: 25495490    Free PMC article.
Highly Cited.
Status of adjuvant endocrine therapy for breast cancer.
Gaia Schiavon, Ian E Smith.
Breast Cancer Res, 2014 Jul 18; 16(2). PMID: 25032258    Free PMC article.
Review.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Annual hazard rates of recurrence for breast cancer after primary therapy.
T Saphner, D C Tormey, R Gray.
J Clin Oncol, 1996 Oct 01; 14(10). PMID: 8874335
Highly Cited.
Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan.
Kazuhiro Suzuki, Mikio Namiki, +3 authors, Hideyuki Akaza.
Jpn J Clin Oncol, 2015 Oct 22; 45(12). PMID: 26486824    Free PMC article.
Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer.
Nobue Kojima, Yui Yamasaki, +2 authors, Hiroki Morita.
Case Rep Obstet Gynecol, 2018 Apr 03; 2018. PMID: 29607235    Free PMC article.
Clinical Studies Investigating the Use of Leuprorelin in Breast Cancer Patients from Asia
Wonshik Han, Hyun Jo Youn.
Asian Pac J Cancer Prev, 2019 May 28; 20(5). PMID: 31127911    Free PMC article.
Review.
Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.
Georges Tanios, Nicolas Andrews Mungo, Aaysha Kapila, Kailash Bajaj.
BMJ Case Rep, 2017 Jul 16; 2017. PMID: 28710301    Free PMC article.
Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.
Ana S Salazar, Malika Rakhmankulova, Laura E Simon, Adetunji T Toriola.
JNCI Cancer Spectr, 2021 Feb 09; 5(1). PMID: 33554041    Free PMC article.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer.
Zhen-Yu Wu, Young-Jin Lee, +10 authors, BeomSeok Ko.
Front Oncol, 2021 May 18; 11. PMID: 33996592    Free PMC article.